These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 37060852)

  • 1. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity.
    Bose G; Healy BC; Saxena S; Saleh F; Glanz BI; Bakshi R; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
    Jiang X; Shen C; Teunissen CE; Wessels M; Zetterberg H; Giovannoni G; Singh CM; Caba B; Elliott C; Fisher E; de Moor C; Belachew S; Gafson AR
    Mult Scler; 2023 Aug; 29(9):1070-1079. PubMed ID: 37317870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
    Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
    Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
    Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosis.
    Juutinen L; Ahinko K; Hagman S; Basnyat P; Jääskeläinen O; Herukka SK; Sumelahti ML
    Mult Scler Relat Disord; 2024 May; 85():105517. PubMed ID: 38442501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.
    Vardakas I; Dorst J; Huss A; Mayer B; Fangerau T; Taranu D; Tumani H; Senel M
    Eur J Neurol; 2024 Aug; 31(8):e16323. PubMed ID: 38700322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
    Monreal E; Fernández-Velasco JI; Álvarez-Lafuente R; Sainz de la Maza S; García-Sánchez MI; Llufriu S; Casanova B; Comabella M; Martínez-Yélamos S; Galimberti D; Ramió-Torrentà L; Martínez-Ginés ML; Aladro Y; Ayuso L; Martínez-Rodríguez JE; Brieva L; Villarrubia N; Eichau S; Zamora J; Rodero-Romero A; Espiño M; Blanco Y; Saiz A; Montalbán X; Tintoré M; Domínguez-Mozo MI; Cuello JP; Romero-Pinel L; Ghezzi L; Pilo de la Fuente B; Pérez-Miralles F; Quiroga-Varela A; Rubio L; Rodríguez-Jorge F; Chico-García JL; Sainz-Amo R; Masjuan J; Costa-Frossard L; Villar LM
    Brain; 2024 Aug; ():. PubMed ID: 39101570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
    J Neurol; 2024 Jul; 271(7):4412-4422. PubMed ID: 38668889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
    Barro C; Healy BC; Saxena S; Glanz BI; Paul A; Polgar-Turcsanyi M; Guttmann CR; Bakshi R; Weiner HL; Chitnis T
    Mult Scler; 2023 Feb; 29(2):206-211. PubMed ID: 36448331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    Fissolo N; Benkert P; Sastre-Garriga J; Mongay-Ochoa N; Vilaseca-Jolonch A; Llufriu S; Blanco Y; Hegen H; Berek K; Perez-Miralles F; Rejdak K; Villar LM; Monreal E; Alvarez-Lafuente R; Soylu OK; Abdelhak A; Bachhuber F; Tumani H; Martínez-Yélamos S; Sánchez-López AJ; García-Merino A; Gutiérrez L; Castillo-Trivino T; Lycke J; Rosenstein I; Furlan R; Filippi M; Téllez N; Ramió-Torrentà L; Lünemann JD; Wiendl H; Eichau S; Khalil M; Kuhle J; Montalban X; Comabella M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):410-418. PubMed ID: 37940409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up.
    Ayrignac X; Aouinti S; Vincent T; Carra-Dallière C; Charif M; Duflos C; Hirtz C; Dos Santos A; Menjot de Champfleur N; Labauge P; Lehmann S
    Mult Scler Relat Disord; 2024 Sep; 89():105747. PubMed ID: 39053395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
    Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.